[HTML][HTML] Role of Immune Cells and Immunotherapy in Multiple Myeloma
The clinical signs of multiple myeloma, a plasma cell (PC) dyscrasia, include bone loss,
renal damage, and paraproteinemia. It can be defined as the uncontrolled growth of …
renal damage, and paraproteinemia. It can be defined as the uncontrolled growth of …
[HTML][HTML] Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma
A Del Dosso, E Tadevosyan, JR Berenson - Oncotarget, 2024 - ncbi.nlm.nih.gov
Multiple myeloma (MM) is the most common primary malignancy of the bone marrow. No
established curative treatment is currently available for patients diagnosed with MM. In …
established curative treatment is currently available for patients diagnosed with MM. In …
A novel pterostilbene compound DCZ0825 induces macrophage M1 differentiation and Th1 polarization to exert anti-myeloma and immunomodulatory
H Zhang, K Hu, Y Lu, Z Xu, G Chen, D Yu, X Gao… - International …, 2024 - Elsevier
Multiple myeloma (MM) is an incurable and recurrent malignancy characterized by abnormal
plasma cell proliferation. There is an urgent need to develop effective drugs in MM …
plasma cell proliferation. There is an urgent need to develop effective drugs in MM …
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone
JR Berenson, A Limon, S Rice, T Safaie, R Boccia… - Targeted Oncology, 2024 - Springer
Background Ruxolitinib (RUX), an orally administered selective Janus kinase 1/2 inhibitor,
has received approval for the treatment of myelofibrosis, polycythemia vera, and graft-versus …
has received approval for the treatment of myelofibrosis, polycythemia vera, and graft-versus …